Want to see SE:BINV full AI Analyst Report?
BINV Stock Chart & Stats
kr23.50
-kr0.05(-0.21%)
At close: 4:00 PM EDT
kr23.50
-kr0.05(-0.21%)
Day’s Range― - ―
52-Week Rangekr19.22 - kr34.85
Previous CloseN/A
Volume69.04K
Average Volume (3M)79.35K
Market Cap
kr1.53B
Enterprise Valuekr1.31B
Total Cash (Recent Filing)kr340.82M
Total Debt (Recent Filing)kr21.47M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Oct 29, 2026EPS Estimate
-1.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.55
Shares Outstanding65,804,360
10 Day Avg. Volume67,092
30 Day Avg. Volume79,348
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.47
Price to Sales (P/S)8.54
P/FCF Ratio-7.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.36
Revenue Forecast (FY)kr49.24M
Bulls Say, Bears Say
Bulls Say
Proprietary Oncology PlatformThe proprietary discovery platform and specialized immune-oncology expertise provide a foundation for generating differentiated antibody candidates. This can support repeated pipeline creation, partnering opportunities, and strategic relevance with larger pharmaceutical companies over the next several quarters.
Low Financial LeverageVery low leverage reduces refinancing and solvency pressure compared with a debt-funded biotech model. It preserves more flexibility to allocate capital toward clinical development and partnerships, although it does not eliminate the need to fund ongoing operating losses.
Strong Gross EconomicsA gross margin near 98% indicates that reported revenue has strong gross-level economics once generated. If pipeline programs or collaborations produce more revenue, this cost structure could allow incremental revenue to contribute meaningfully toward covering research and corporate expenses.
Bears Say
Severe Revenue ContractionThe steep TTM revenue decline shows that current income generation is not stable, which is significant for a clinical-stage company reliant on collaborations and milestone-related inflows. Sustained weakness would limit internal funding capacity and increase dependence on future deals or financing.
Persistent Cash BurnSubstantial negative operating and free cash flow means the company is consuming capital to maintain its activities rather than funding them internally. Unless spending falls or revenue ramps materially, continued external funding may be required, creating ongoing financing and dilution pressure.
Deep Structural LossesDeeply negative profitability indicates that the current business remains structurally loss-making despite its high gross margin. Persistent operating losses can constrain investment flexibility and weaken shareholder value creation until clinical, licensing, or commercial revenue scales sufficiently.
BioInvent International AB News
BINV FAQ
What was BioInvent International AB’s price range in the past 12 months?
BioInvent International AB lowest stock price was kr19.22 and its highest was kr34.85 in the past 12 months.
What is BioInvent International AB’s market cap?
BioInvent International AB’s market cap is kr1.53B.
When is BioInvent International AB’s upcoming earnings report date?
BioInvent International AB’s upcoming earnings report date is Oct 29, 2026 which is in 17 days.
How were BioInvent International AB’s earnings last quarter?
BioInvent International AB released its earnings results on Aug 27, 2026. The company reported -kr1.868 earnings per share for the quarter, beating the consensus estimate of -kr1.899 by kr0.031.
Is BioInvent International AB overvalued?
According to Wall Street analysts BioInvent International AB’s price is currently Overvalued.
Does BioInvent International AB pay dividends?
BioInvent International AB does not currently pay dividends.
What is BioInvent International AB’s EPS estimate?
BioInvent International AB’s EPS estimate is -1.98.
How many shares outstanding does BioInvent International AB have?
BioInvent International AB has 65,804,360 shares outstanding.
What happened to BioInvent International AB’s price movement after its last earnings report?
BioInvent International AB reported an EPS of -kr1.868 in its last earnings report, beating expectations of -kr1.899. Following the earnings report the stock price went down -3.83%.
Which hedge fund is a major shareholder of BioInvent International AB?
Currently, no hedge funds are holding shares in SE:BINV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioInvent International AB
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. Its most advanced therapeutic candidate, BI-1206, targets non-Hodgkin lymphoma and various solid tumors. The company's diverse pipeline also features developments aimed at tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system, alongside BT-001 for solid tumors. Furthermore, BioInvent is progressing BI-1808 and BI-1910, a pair of anti-TNFR2 antibodies, designed to combat solid tumors and cutaneous T-cell lymphoma. Strategic collaborations are integral to its operations; these include a partnership with Pfizer Inc. for antibody development against tumor-associated myeloid cells, a co-development effort with Transgene involving multi-functional oncolytic viruses for solid tumors, and an agreement with Merck for the clinical advancement and supply of BI-1808. Established in 1996, BioInvent is based in Lund, Sweden.
Technical Analysis
Alligator Bioscience AB
―
Oncopeptides AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―